Sorafenib tosylate is primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and hepatocellular carcinoma (liver cancer). It works by inhibiting multiple kinases involved in tumor growth and angiogenesis, effectively slowing the progression of these cancers. Additionally, it is sometimes prescribed for differentiated thyroid carcinoma that is resistant to radioactive iodine therapy. The drug is administered orally, allowing for convenient outpatient treatment. Patients typically undergo regular monitoring to manage potential side effects, such as hypertension, skin reactions, and gastrointestinal issues. Its targeted action makes it a valuable option for patients with limited treatment alternatives.